Overview

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinom

Status:
Terminated

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-21 when given with liposomal doxorubicin on day 1 of every 28 day cycle Phase II will commence once the MTD is established, additional subjects will be enrolled and receive oral lenalidomide on days 1-21 with liposomal doxorubicinon day 1 in 28 day cycles until disease progression is documented.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Celgene Corporation

Collaborator:

Prologue Research International

Treatments:

Doxorubicin
Lenalidomide
Liposomal doxorubicin